12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kynamro mipomersen regulatory update

Sanofi said its Genzyme Corp. subsidiary submitted an MAA to EMA for Kynamro mipomersen to treat homozygous...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >